Cybin Inc. (CYBN)
USD 6.5
(-1.81%)
USD 6.5
(-1.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -78.57 Million CAD | -43.67% |
| 2022 | -51.28 Million CAD | 13.77% |
| 2021 | -63.67 Million CAD | -108.55% |
| 2020 | -32.16 Million CAD | -316922.92% |
| 2019 | 9600.00 CAD | 111.92% |
| 2018 | -80.52 Thousand CAD | 0.0% |
| 2016 | -127.22 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -20.17 Million CAD | 19.74% |
| 2023 Q3 | -26.88 Million CAD | -70.06% |
| 2023 FY | - CAD | -43.37% |
| 2023 Q4 | -28.56 Million CAD | -6.24% |
| 2023 Q2 | -15.8 Million CAD | -16.59% |
| 2023 Q1 | -13.55 Million CAD | -0.65% |
| 2022 Q4 | -13.47 Million CAD | -1.92% |
| 2022 Q3 | -13.21 Million CAD | 8.53% |
| 2022 Q1 | -13.55 Million CAD | 16.37% |
| 2022 Q2 | -14.44 Million CAD | -6.56% |
| 2022 FY | - CAD | 13.77% |
| 2021 Q2 | -17.06 Million CAD | -23.14% |
| 2021 Q3 | -16.45 Million CAD | 3.57% |
| 2021 Q1 | -13.85 Million CAD | -12.82% |
| 2021 FY | - CAD | -108.55% |
| 2021 Q4 | -16.21 Million CAD | 1.48% |
| 2020 FY | - CAD | -316922.92% |
| 2020 Q3 | -11.35 Million CAD | -23116.16% |
| 2020 Q4 | -12.28 Million CAD | -8.19% |
| 2020 Q2 | -48.89 Thousand CAD | 98.84% |
| 2020 Q1 | -4.22 Million CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 FY | - CAD | 111.92% |
| 2018 FY | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | -148.046% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | -96.844% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | -53.679% |
| Azitra, Inc. | -10.67 Million USD | -636.199% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -860.587% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -1045.042% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | -174.741% |
| CEL-SCI Corporation | -27.56 Million USD | -185.103% |
| iBio, Inc. | -14.02 Million USD | -460.417% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -217.697% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -289.33% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | -244.254% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -1537.0% |
| NanoViricides, Inc. | -7.75 Million USD | -912.956% |
| Oragenics, Inc. | -20.87 Million USD | -276.367% |
| BiomX Inc. | -22.81 Million USD | -244.405% |
| BiomX Inc. | -22.81 Million USD | -244.405% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 774.414% |
| Palatin Technologies, Inc. | -29.03 Million USD | -170.661% |
| Scorpius Holdings, Inc. | -35.08 Million USD | -123.975% |
| Theriva Biologics, Inc. | -19.85 Million USD | -295.769% |